New World Monkey
            <i>Aotus nancymae</i>
            as a Model for
            <i>Campylobacter jejuni</i>
            Infection and Immunity

Jones, Franca R.; Baqar, Shahida; Gozalo, Alfonso S; Núñez, Gladys; Espinoza, Nereyda; Reyes, Sharina; Salazar, Milagros; Meza, Rina; Porter, Chad K.; Walz, S E

doi:10.1128/iai.74.1.790-793.2006

Cited by 33 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The C. jejuni CPS conjugate vaccines synthesized in this study were immunogenic in mice and reduced the disease following intranasal challenge (9) with the homologous strain of C. jejuni. We also show here that the 81-176 CPS conjugate vaccine is immunogenic and 100% protective against diarrheal disease in New World monkeys (26).…”

mentioning

confidence: 91%

“…Challenge of A. nancymaae with 81-176 has been described previously (26). Basically, monkeys were injected intramuscularly with ranitidine (1.5 mg/kg body weight; Zantac, GlaxoSmithKline) 90 min prior to C. jejuni inoculation.…”

Section: Methodsmentioning

confidence: 99%

“…Bacterial cells for capsule extraction were grown in brain heart infusion medium at 37°C in a microaerophilic environment as described previously (11,28). Growth of bacteria for mouse and monkey experiments has been described previously (9,26).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Capsule Polysaccharide Conjugate Vaccine against Diarrheal Disease Caused by Campylobacter jejuni

et al. 2009

Self Cite

View full text Add to dashboard Cite

The capsule polysaccharide (CPS) of Campylobacter jejuni is one of the few identified virulence determinants of this important human pathogen. Since CPS conjugate vaccines have been so effective against other mucosal pathogens, we evaluated this approach using CPSs from two strains of C. jejuni, 81-176 (HS23 and HS36 serotype complex) and CG8486 (HS4 serotype complex). The CPSs of 81-176 and CG8486 were independently linked to the carrier protein CRM 197 by reductive amination between an aldehyde(s), strategically created at the nonreducing end of each CPS, and accessible amines of CRM 197 . In both cases, the CPS:CRM 197 ratio used was 2:1 by weight. Mass spectrometry and gel electrophoresis showed that on average, each glycoconjugate preparation contained, at least in part, two to five CPSs attached to one CRM 197 . When administered subcutaneously to mice, these vaccines elicited robust immune responses and significantly reduced the disease following intranasal challenge with the homologous strains of C. jejuni. The CPS 81-176 -CRM 197 vaccine also provided 100% protection against diarrhea in the New World monkey Aotus nancymaae following orogastric challenge with C. jejuni 81-176.

show abstract

mentioning

confidence: 91%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Capsule Polysaccharide Conjugate Vaccine against Diarrheal Disease Caused by Campylobacter jejuni

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…The A. nancymaae model has been used to evaluate the immunogenicity and efficacy of several ETEC (15) and Campylobacter (14,27) vaccines. The attack rates in naive Aotus monkeys orally inoculated with 5 ϫ 10 11 to 7 ϫ 10 11 CFU of C. jejuni are typically Ն70%.…”

Section: Discussionmentioning

confidence: 99%

“…Both Aotus challenge models result in reproducible attack rates of Ն70% and are characterized by colonization of the gastrointestinal tract and the induction of diarrhea (14,15). The addition of a Shigella-Aotus challenge model would enable the testing of potential combination vaccines against the three most common enteric bacterial pathogens responsible for traveler's diarrhea.…”

mentioning

confidence: 99%

Development of an Aotus nancymaae Model for Shigella Vaccine Immunogenicity and Efficacy Studies

Gregory¹,

Kaminski²,

Lugo‐Roman³

et al. 2014

Infect Immun

View full text Add to dashboard Cite

Several animal models exist to evaluate the immunogenicity and protective efficacy of candidate Shigella vaccines. The two most widely used nonprimate models for vaccine development include a murine pulmonary challenge model and a guinea pig keratoconjunctivitis model. Nonhuman primate models exhibit clinical features and gross and microscopic colonic lesions that mimic those induced in human shigellosis. Challenge models for enterotoxigenic Escherichia coli (ETEC) and Campylobacter spp. have been successfully developed with Aotus nancymaae, and the addition of a Shigella-Aotus challenge model would facilitate the testing of combination vaccines. A series of experiments were designed to identify the dose of Shigella flexneri 2a strain 2457T that induces an attack rate of 75% in the Aotus monkey. After primary challenge, the dose required to induce an attack rate of 75% was calculated to be 1 ؋ 10 11 CFU. Shigella-specific immune responses were low after primary challenge and subsequently boosted upon rechallenge. However, preexisting immunity derived from the primary challenge was insufficient to protect against the homologous Shigella serotype. A successive study in A. nancymaae evaluated the ability of multiple oral immunizations with live-attenuated Shigella vaccine strain SC602 to protect against challenge. After three oral immunizations, animals were challenged with S. flexneri 2a 2457T. A 70% attack rate was demonstrated in control animals, whereas animals immunized with vaccine strain SC602 were protected from challenge (efficacy of 80%; P ‫؍‬ 0.05). The overall study results indicate that the Shigella-Aotus nancymaae challenge model may be a valuable tool for evaluating vaccine efficacy and investigating immune correlates of protection.

show abstract

Campylobacter jejuni: Molecular Mechanisms and Animal Models of Colonization and Disease

Gourley

Konkel

2015

Human Emerging and Re‐emerging Infections

View full text Add to dashboard Cite

New World Monkey Aotus nancymae as a Model for Campylobacter jejuni Infection and Immunity

Cited by 33 publications

References 26 publications

Capsule Polysaccharide Conjugate Vaccine against Diarrheal Disease Caused by Campylobacter jejuni

Capsule Polysaccharide Conjugate Vaccine against Diarrheal Disease Caused by Campylobacter jejuni

Development of an Aotus nancymaae Model for Shigella Vaccine Immunogenicity and Efficacy Studies

Campylobacter jejuni: Molecular Mechanisms and Animal Models of Colonization and Disease

Contact Info

Product

Resources

About